Panelists discuss the efficacy and safety of KRAS inhibitors for non–-small cell lung cancer (NSCLC), evaluating clinical trial results and their potential impact on treatment strategies.

The FDA has granted AUTX-703, a first-in-class oral KAT2A/B degrader, fast track designation for the treatment of ...

The FDA granted priority review to pembrolizumab for neoadjuvant and adjuvant use in head and neck squamous cell carcinoma, ...

A study found that sonodynamic therapy showed no adverse events and demonstrated cancer cell death in 3 patients with ...

Colton Ladbury, MD, discusses radiation therapy for hematologic malignancies, total marrow irradiation, and findings that were presented during the American Society for Radiation Oncology Annual ...